deltatrials
Completed PHASE4 INTERVENTIONAL 3-arm NCT06020118

Comparative Immunogenicity of Concomitant vs Sequential mRNA COVID-19 and Influenza Vaccinations

Randomized Study of the Immunogenicity and Duration of Antibody Response Against Circulating SARS-CoV-2 Variant and Influenza Viruses Following Concomitant Versus Sequential Administration of mRNA COVID-19 Vaccine and Quadrivalent Cell Culture-based Influenza Vaccine Among Children and Adults

Sponsor: Arizona State University

Conditions COVID-19 Influenza
Interventions Sequential Vaccination (Influenza vaccine then mRNA COVID booster) Sequential Vaccination (mRNA COVID booster then Influenza vaccine) Simultaneous Vaccination (Influenza Vaccine and mRNA COVID booster)
Updated 12 times since 2023 Last updated: Jun 11, 2025 Started: Sep 25, 2023 Primary completion: Mar 7, 2024 Completion: May 17, 2024
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

This PHASE4 trial investigates COVID-19 and Influenza and is currently completed. Arizona State University leads this study, which shows 12 recorded versions since 2023 — indicating substantial longitudinal coverage. Longitudinal tracking of infectious disease trials helps identify durability of treatment effects.

Status Flow

~Sep 2023 – ~Oct 2023 · 30 days · monthly snapshot~Oct 2023 – ~Nov 2023 · 31 days · monthly snapshot~Nov 2023 – ~Dec 2023 · 30 days · monthly snapshot~Dec 2023 – ~Jan 2024 · 31 days · monthly snapshot~Jan 2024 – ~Mar 2024 · 2 months · monthly snapshot~Mar 2024 – ~Apr 2024 · 31 days · monthly snapshot~Apr 2024 – ~Jun 2024 · 2 months · monthly snapshot~Jun 2024 – ~Jul 2024 · 30 days · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Jul 2025 · 10 months · monthly snapshotCompleted~Jul 2025 – ~Sep 2025 · 2 months · monthly snapshot~Sep 2025 – present · 8 months · monthly snapshotCompleted

Change History

12 versions recorded

  1. Sep 2025 — Present [monthly]

    Completed PHASE4

  2. Jul 2025 — Sep 2025 [monthly]

    Completed PHASE4

  3. Sep 2024 — Jul 2025 [monthly]

    Completed PHASE4

  4. Jul 2024 — Sep 2024 [monthly]

    Completed PHASE4

  5. Jun 2024 — Jul 2024 [monthly]

    Completed PHASE4

    Status: Active Not Recruiting → Completed

▶ Show 7 earlier versions

  1. Apr 2024 — Jun 2024 [monthly]

    Active Not Recruiting PHASE4

  2. Mar 2024 — Apr 2024 [monthly]

    Active Not Recruiting PHASE4

  3. Jan 2024 — Mar 2024 [monthly]

    Active Not Recruiting PHASE4

    Status: Recruiting → Active Not Recruiting

  4. Dec 2023 — Jan 2024 [monthly]

    Recruiting PHASE4

  5. Nov 2023 — Dec 2023 [monthly]

    Recruiting PHASE4

    Status: Not Yet Recruiting → Recruiting

  6. Oct 2023 — Nov 2023 [monthly]

    Not Yet Recruiting PHASE4

  7. Sep 2023 — Oct 2023 [monthly]

    Not Yet Recruiting PHASE4

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Arizona State University
  • Centers for Disease Control and Prevention
  • Cleveland VA Medical Center
  • Duke University
  • Senders Pediatrics
  • University Hospitals Cleveland Medical Center
  • University of Pittsburgh
  • Valleywise Health
  • Washington University School of Medicine
Data source: Duke University

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations